High circulating levels of GIP have shown beneficial effects on the lipid profile in humans (Møller et al., 2016), and treatment with GIPR/GLP-1R co-agonists have shown improvement of the lipid profile in patients with T2D (Frias et al., 2017, 2018). Here, GIPR is linked to type 2 diabetes mellitus.